Opendata, web and dolomites


The First non-cancerogenic Glyoxal Acid-Free fixative for a Formalin-free hospital

Total Cost €


EC-Contrib. €






 GAF project word cloud

Explore the words cloud of the GAF project. It provides you a very rough idea of what is the project "GAF" about.

therapy    structural    carcinogenic    medical    validate    feasibility    molecular    valid    second    initially    plan    fixation    capacity    acid    biosciences    finance    hospitals    phases    pathological    first    scientific    addax    private    public    tissues    cancerogenic    represented    faster    outsourcing    services    time    segment    labs    born    pathology    accepted    replace    quality    torino    proposes    entities    performing    fixative    formalin    diagnosis    primarily    optimal    market    agreements    community    commercialization    business    clients    preserve    retain    prohibited    correct    toxicity    investments    substance    guarantee    patient    model    scenario    spin    university    diagnostic    solution    free    innovative    emergency    clinics    huge    reagent    chemical    healthcare    cros    serve    veterinary    absence    glyoxal    addressable    gaf    combined    pharmaceutical    academic    proof    updated    introducing    founders    institutes    formaldehyde    2017    company    august    preserving    forensic    tissue    customers    alternative    specimens    laboratories    union    producers    off   

Project "GAF" data sheet

The following table provides information about the project.


Organization address
city: TORINO
postcode: 10123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADDAX BIOSCIENCES SRL IT (TORINO) coordinator 50˙000.00


 Project objective

ADDAX Biosciences is an academic spin-off of the University of Torino, born after long time research activity of its founders on the pathological tissues. Our company goal is to replace the use of Formalin (a cancerogenic solution of formaldehyde) as fixative, while preserving optimal tissue fixation to guarantee correct diagnosis and therapy. In the European Union, Formaldehyde is recognized as a carcinogenic substance, and its use, production and commercialization is prohibited from August 2017. However, at present there is no valid alternative to Formalin accepted by the scientific community to preserve patient specimens. Our project proposes a huge step forward in the fixative market by introducing an innovative reagent, based on acid-free Glyoxal (GAF), that will allow the optimal tissue fixation at structural and molecular level, combined with the absence of toxicity and carcinogenic activity. The addressable market of our GAF product is primarily represented by the healthcare segment, thus the targeted users and clients are public and private entities performing pathology services, such as: Hospitals, Clinics, Emergency Medical Services, Diagnostic Laboratories, Academic Institutes, Forensic Laboratories, CROs, Veterinary Clinics, Labs and Hospitals. Our business model is initially based in two distinct phases: the first one aimed to achieve a controlled production capacity to serve the first customers and finance the further investments; in the second phase, from second year, we expect a faster scale-up through outsourcing production agreements with major European producers of chemical and pharmaceutical products. In this scenario, Addax will retain the R&D, quality, scientific and market development. The objectives of our Feasibility Study are to validate at European level our proof-of-concept and design an updated Business Plan and Commercialization Plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GAF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GAF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More